How is normohormonal hyperparathyroidism (NHpHPT) typically identified?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How Normohormonal Hyperparathyroidism (NHpHPT) is Typically Found

Normohormonal hyperparathyroidism is typically discovered incidentally during routine biochemical screening that reveals hypercalcemia (calcium >10.2 mg/dL) with parathyroid hormone levels that fall within the normal laboratory reference range, though these "normal" PTH values are physiologically inappropriate for the elevated calcium. 1

Clinical Context of Discovery

Asymptomatic Detection (Most Common)

The majority of NHpHPT cases are found asymptomatically, mirroring the broader trend in primary hyperparathyroidism where 80-90% of cases lack overt symptoms 1. The diagnosis emerges when:

  • Routine blood work reveals elevated calcium levels, prompting PTH measurement that returns within normal laboratory ranges
  • Evaluation for osteoporosis or bone density screening uncovers the biochemical abnormality 1
  • Kidney stone workup leads to calcium and PTH assessment 1

Symptomatic Presentations

When symptoms are present, patients may present with 1:

  • Osteoarticular pain or low-energy fractures
  • Renal lithiasis (kidney stones) - notably more common in NHpHPT than classic PHPT 2
  • Osteoporosis or vertebral compression fractures
  • Polyuria-polydipsia syndrome

The Diagnostic Challenge

The key diagnostic feature is recognizing that a "normal" PTH level is actually inappropriate in the setting of hypercalcemia 1. In healthy individuals, elevated calcium should suppress PTH secretion; failure to suppress indicates autonomous parathyroid function.

Biochemical Criteria for NHpHPT

  • Calcium: >10.2 mg/dL (or >2.55 mmol/L)
  • PTH: Within normal laboratory reference range (typically <65 pg/mL)
  • Fractional excretion of calcium (FeCa): >2% 1

Important Diagnostic Pitfalls

The 2025 French guidelines emphasize critical steps before accepting the diagnosis 1:

  1. Vitamin D status must be normalized for >6 months - Vitamin D deficiency can cause secondary hyperparathyroidism that confounds the picture

  2. Exclude other causes of secondary hyperparathyroidism:

    • Insufficient calcium intake (use dietary questionnaire)
    • Renal insufficiency
    • Malabsorption (bariatric surgery, celiac disease, inflammatory bowel disease)
    • Medications (loop diuretics, bisphosphonates, denosumab)
  3. Measure ionized calcium when total calcium is borderline or in the upper normal range 1

  4. Consider oral calcium loading test - This can help differentiate primary from secondary hyperparathyroidism when the diagnosis remains unclear. In NHpHPT, calcium loading produces hypercalcemia without PTH suppression 1

Prevalence and Recognition

NHpHPT represents approximately 5.5-22.5% of all primary hyperparathyroidism cases 3, 2, though this varies by series. Research shows that PTH levels in NHpHPT can be remarkably low - as low as 5 pg/mL - while still representing autonomous parathyroid function 3.

Why It's Missed

Clinicians often delay diagnosis because "normal" PTH levels falsely reassure them 3. The 2011 study by Lew et al. found that nearly all NHpHPT patients underwent additional testing that delayed surgery, unlike patients with elevated PTH who proceeded more directly to treatment 3.

Systematic Workup Once Identified

The 2025 guidelines mandate comprehensive target organ assessment 4:

Renal evaluation:

  • Glomerular filtration rate
  • 24-hour urine calcium
  • Renal imaging (CT scan preferred over ultrasound for detecting stones/nephrocalcinosis)

Bone evaluation:

  • Bone densitometry at three sites (lumbar spine, femur, radius)
  • Vertebral imaging for asymptomatic fractures
  • Height measurement and assessment for kyphosis

Key Clinical Pearls

  • Lower PTH set points exist in some individuals - what appears "normal" is actually pathologic for that patient's calcium level 3
  • Imaging localization is less accurate in NHpHPT compared to classic PHPT, with lower concordance between ultrasound and sestamibi scanning 5
  • Multigland disease is more common in NHpHPT (approximately 20% vs 11% in classic PHPT) 2
  • Smaller adenomas are typical, with mean gland weights roughly half that of classic PHPT 5, 2

The recognition of NHpHPT requires a high index of suspicion and understanding that any detectable PTH in the setting of hypercalcemia represents inappropriate secretion, regardless of whether it falls within laboratory reference ranges 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.